Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.

Headquartered in Denmark, Novo Nordisk employs approximately 32,500 employees in 74 countries, and markets its products in 179 countries.

Career

At Novo Nordisk we offer you a life changing career. With offices in 74 countries and a product portfolio that spans the globe, Novo Nordisk is the world leader in diabetes care and has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. We lead because we go beyond employing people with skills: we employ ambitious people who are committed to making a difference. You’ll find that we demand your utmost ambition and dedication, and that we’ll reward your hard work with once-in-lifetime opportunities for development and growth.

Graduate Programme – Click here to learn more about our graduate programme

Novo Nordisk in China

Novo Nordisk (China) Pharmaceutical Co., Ltd. was established in 1994, headquartered in Beijing with a sales network with local hubs in Beijing, Shanghai, Guangzhou, Shenyang, Wuhan, Jinan and Hong Kong to distribute products and services throughout all of China’s provinces.

Novo Nordisk established Novo Nordisk (China) R&D Centre in Beijing Economic-Technological Development Area in 2002, the first R&D centre established in China by an international bio-pharmaceutical company focusing on biotech.

In November 2008, Novo Nordisk started construction on a new insulin production plant in Tianjin, China. It is expected to be operational in 2012.

The Novo Nordisk Way

In 1923 our Danish founders began a journey to change diabetes. Today, we are thousands of employees across the world with the passion, the skills and the commitment to continue this journey to prevent, treat and ultimately cure diabetes.

• Our ambition is to strengthen our leadership in diabetes.
• We aspire to change possibilities in haemophilia and other serious chronic conditions where we can make a difference.
• Our key contribution is to discover and develop innovative biological medicines and make them accessible to patients throughout the world.
• Growing our business and delivering competitive financial results is what allows us to help patients live better lives, offer an attractive return to our shareholders and contribute to our communities.
• Our business philosophy is one of balancing financial, social and environmental considerations – we call it ‘The Triple Bottom Line’.
• We are open and honest, ambitious and accountable, and treat everyone with respect.
• We offer opportunities for our people to realise their potential.
• We never compromise on quality and business ethics.
• Every day we must make difficult choices always keeping in mind, what is best for patients, our employees and our shareholders in the long run.

It’s the Novo Nordisk Way.